Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMA-HF pemafibrate trial in heart failure with diabetes and hypertriglyceridemia
jRCTs051240124Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in heart failure (HF), type 2 diabetes mellitus (T2DM) and hypertriglyceridemia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in BMIPP SPECT washout rate. Started Aug 2025; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)hypertriglyceridemia
Beyond the preview
Go deeper on jRCTs051240124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240124.